Plano, TX, United States of America

Dan Flynn

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: At&t Intellectual Property I, LP. Active years: 2020-2022.

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2020-2022

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Dan Flynn: Innovator in Database Systems

Introduction

Dan Flynn is a notable inventor based in Plano, TX (US). He has made significant contributions to the field of database systems, holding a total of 2 patents. His work focuses on enhancing access control mechanisms within database environments.

Latest Patents

One of Dan Flynn's latest patents is titled "Database System Consensus-Based Access Control." This innovative processing system is designed to obtain an operations set associated with database sources from a client entity. The operations set includes a statement that contains a query. The system identifies data sets from the operations set and transmits requests to the respective owners for access permissions. Upon receiving approvals, the system retrieves portions of data from the approved data sets, executes the operations, and provides the client entity with access to the resulting data set.

Career Highlights

Dan Flynn is currently employed at AT&T Intellectual Property I, LP, where he continues to develop and refine his innovative ideas. His work has been instrumental in advancing the capabilities of database systems, particularly in the area of access control.

Collaborations

Dan collaborates with Andrew Vishnyakov, contributing to the development of cutting-edge technologies in their field.

Conclusion

Dan Flynn's contributions to database systems through his patents demonstrate his commitment to innovation and excellence in technology. His work continues to influence the way data access is managed in modern systems.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…